| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $756,002 | 2 | 67 |
Sells | $72,045 | 1 | 33 |
| Smith Scott Andrew | Chief Executive Officer | 2 | $756,002 | 0 | $0 | $756,002 |
| Le Goff Corinne | Chief Commercial Officer | 0 | $0 | 1 | $72,045 | $-72,045 |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Over the last 12 months, insiders at Viatris Inc. have bought $756,002 and sold $72,045 worth of Viatris Inc. stock.
On average, over the past 5 years, insiders at Viatris Inc. have bought $472,917 and sold $6.11M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Smith Scott Andrew (Chief Executive Officer) — $756,002.
The last purchase of 22,000 shares for transaction amount of $219,740 was made by Smith Scott Andrew (Chief Executive Officer) on 2025‑08‑12.
| 2025-09-11 | Sale | Le Goff Corinne | Chief Commercial Officer | 7,032 0.0006% | $10.25 | $72,045 | +10.15% | |
| 2025-08-12 | Smith Scott Andrew | Chief Executive Officer | 22,000 0.0019% | $9.99 | $219,740 | +7.33% | ||
| 2025-05-12 | Smith Scott Andrew | Chief Executive Officer | 60,000 0.0051% | $8.94 | $536,262 | +18.54% | ||
| 2024-11-11 | Sale | Campbell Paul | See Remarks | 26,925 0.0022% | $12.88 | $346,686 | -20.99% | |
| 2024-09-12 | Sale | Malik Rajiv | director | 200,000 0.0166% | $11.67 | $2.33M | -7.31% | |
| 2024-08-30 | Sale | Malik Rajiv | director | 50,000 0.0042% | $12.00 | $600,000 | -9.57% | |
| 2024-08-28 | Sale | Malik Rajiv | director | 50,000 0.0042% | $11.90 | $595,075 | -8.07% | |
| 2024-08-23 | Sale | Malik Rajiv | director | 100,000 0.0084% | $11.75 | $1.18M | -6.49% | |
| 2024-08-22 | Sale | Malik Rajiv | director | 100,000 0.0084% | $11.73 | $1.17M | -5.04% | |
| 2024-08-21 | Sale | Malik Rajiv | director | 100,000 0.0084% | $11.75 | $1.18M | -5.21% | |
| 2024-06-14 | Sale | Malik Rajiv | director | 264,300 0.0212% | $10.18 | $2.69M | +12.75% | |
| 2024-06-13 | Sale | Malik Rajiv | director | 85,660 0.0071% | $10.52 | $900,741 | +10.26% | |
| 2024-05-28 | Sale | Roman Brian | Chief Legal Officer | 89,419 0.0075% | $10.38 | $928,429 | +10.26% | |
| 2024-03-13 | Sale | Mauro Anthony | See Remarks | 250,000 0.0211% | $12.09 | $3.02M | -2.65% | |
| 2024-03-05 | Sale | Campbell Paul | See Remarks | 24,353 0.0021% | $12.33 | $300,272 | -3.25% | |
| 2024-03-05 | Sale | Lyons Dillon JoEllen | director | 20,000 0.0017% | $12.36 | $247,200 | -3.25% | |
| 2024-03-04 | Sale | Ni Xiangyang (Sean) | President, Greater China | 21,532 0.0018% | $12.51 | $269,314 | -3.89% | |
| 2024-02-23 | Sale | Cuneo Andrew | See Remarks | 4,000 0.0003% | $13.50 | $54,000 | -11.96% | |
| 2024-02-15 | Sale | Cuneo Andrew | See Remarks | 4,000 0.0003% | $12.50 | $50,000 | -7.04% | |
| 2024-01-04 | Sale | Cuneo Andrew | See Remarks | 4,000 0.0003% | $11.50 | $46,000 | +3.22% |
| Smith Scott Andrew | Chief Executive Officer | 314807 0.0273% | $4.63M | 2 | 0 | |
| Le Goff Corinne | Chief Commercial Officer | 35299 0.0031% | $519,248.29 | 0 | 1 | |
| Mauro Anthony | See Remarks | 243044 0.0211% | $3.58M | 0 | 1 | |
| GOETTLER MICHAEL | Chief Executive Officer | 136796 0.0119% | $2.01M | 1 | 0 | +8.94% |
| Campbell Paul | See Remarks | 126901 0.011% | $1.87M | 0 | 2 | |
| KORMAN HARRY | director | 94960 0.0082% | $1.4M | 10 | 0 | <0.0001% |
| Ni Xiangyang (Sean) | President, Greater China | 90804 0.0079% | $1.34M | 0 | 6 | |
| Roman Brian | Chief Legal Officer | 67723 0.0059% | $996,205.33 | 0 | 1 | |
| KILTS JAMES M | director | 64905 0.0056% | $954,752.55 | 1 | 0 | <0.0001% |
| Lyons Dillon JoEllen | director | 58714 0.0051% | $863,682.94 | 0 | 1 | |
| Cuneo Andrew | See Remarks | 34795 0.003% | $511,834.45 | 0 | 4 | |
| CORNWELL W DON | 22031 0.0019% | $324,076.01 | 4 | 0 | <0.0001% | |
| van der Meer Mohr Pauline | 20543 0.0018% | $302,187.53 | 0 | 1 | ||
| COURY ROBERT J | Executive Chairman | 0 0% | $0 | 0 | 2 | |
| Malik Rajiv | director | 0 0% | $0 | 0 | 8 | |
| Taddese Menassie | See Remarks | 0 0% | $0 | 0 | 1 |
$910,099,463 | 123 | 11.52% | $2.08B | |
$25,130,034 | 62 | -7.01% | $12.13B | |
$14,599,168 | 59 | 12.79% | $1.72B | |
$102,709,455 | 46 | 30.55% | $983.47M | |
$11,542,910 | 40 | 56.19% | $1.45B | |
$21,020,549 | 38 | -2.84% | $13.39B | |
$73,312,053 | 38 | -4.37% | $1.61B | |
$12,998,723 | 30 | 3.46% | $4.18B | |
$6,506,230 | 27 | -16.20% | $1B | |
$78,335,024 | 20 | 4.76% | $55.52B | |
$25,034,841 | 20 | 9.38% | $608.42M | |
$83,406,412 | 19 | 21.96% | $3.19B | |
Viatris Inc. (VTRS) | $2,233,486 | 16 | -3.34% | $16.94B |
$1,843,996 | 10 | 22.92% | $917.21M | |
$1,718,514 | 9 | 38.13% | $739.11M | |
$26,633,903 | 9 | 42.23% | $1.25B | |
$141,200 | 8 | 41.74% | $5.29B | |
$614,633 | 6 | 27.86% | $2.1B | |
$32,954,224 | 5 | -0.22% | $37.73B |
| Increased Positions | 484 | +44.32% | 79M | +8.01% |
| Decreased Positions | 442 | -40.48% | 86M | -8.73% |
| New Positions | 141 | New | 14M | New |
| Sold Out Positions | 105 | Sold Out | 19M | Sold Out |
| Total Postitions | 1,134 | +3.85% | 983M | -0.72% |
| Vanguard Group Inc | $1.75M | 12.18% | 140.27M | -5M | -3.34% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $1.05M | 7.3% | 84.06M | +5M | +6.72% | 2025-09-30 |
| Blackrock, Inc. | $1.02M | 7.12% | 81.96M | -901,508 | -1.09% | 2025-09-30 |
| Davis Selected Advisers | $864,047.00 | 6.02% | 69.35M | +3M | +4.47% | 2025-09-30 |
| State Street Corp | $694,114.00 | 4.84% | 55.71M | +419,662 | +0.76% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $465,634.00 | 3.24% | 37.37M | +6M | +19.53% | 2025-09-30 |
| Geode Capital Management, Llc | $372,760.00 | 2.6% | 29.92M | -1M | -4.19% | 2025-09-30 |
| Ameriprise Financial Inc | $346,673.00 | 2.42% | 27.82M | +5M | +20.16% | 2025-09-30 |
| Invesco Ltd. | $315,285.00 | 2.2% | 25.3M | -2M | -8.41% | 2025-09-30 |
| Deerfield Management Company, L.P. | $300,275.00 | 2.09% | 24.1M | +75,176 | +0.31% | 2025-09-30 |